Pitolisant Shows Promise for Prader-Willi Syndrome Symptoms
Harmony announced new data from its phase 2 study evaluating pitolisant for excessive daytime sleepiness in Prader-Willi syndrome.
Source: sleepreviewmag.com
Stay updated with breaking news from Aberrant Behavioral. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Harmony announced new data from its phase 2 study evaluating pitolisant for excessive daytime sleepiness in Prader-Willi syndrome.
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...